Abstract Library

#937 Real-World Study on Everolimus in Advanced, Progressive Neuroendocrine Tumors

Introduction: Everolimus (EVE) is a valid therapeutic option for neuroendocrine tumors (NETs). However, data in the “real-world” setting outside regulatory trials are scant.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Panzuto F, Rinzivillo M, Fazio N, De Braud F, Luppi G,

Keywords: Everolimus, compassionate use,

#479 Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Everolimus is a treatment option for patients with pancreatic NETs, while its use in patients with gastrointestinal NETs still remains to be defined.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Ambrosio M, Guerra A, Lupo S, Bondanelli M, Sartori S,

Keywords: Everolimus, GEP-NET, efficacy, side effects,

#48 Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma

Introduction: Medullary thyroid carcinoma (MTC) accounts for about 5-10% of all thyroid cancers, and while disease localized to the thyroid can be cured by surgery, there is no effective treatment for disseminated MTC. Constitutive activation of the RET proto-oncogene is implicated in familial and a proportion of sporadic cases, and up-regulates the AKT/PI3-kinase/mTOR signal transduction pathway. Recent studies have shown that the inhibitor of mTOR, everolimus (RAD001, Novartis, Basel), can inhibit the proliferation of the TT cell line and human MTC tumor cells in vitro. Clinically, everolimus has been shown to attenuate the progression of some gastrointestinal neuroendocrine tumors, but its clinical use in MTC has not yet been evaluated.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Druce M, Maher K, Grozinsky-Glasberg S, Gross D, Chambers J,

Keywords: medullary thyroid cancer, calcitonin, everolimus, RAD001,